GSK (GSK)

Sector:

Pharma and Biotech

Index:

FTSE 100

1,514.50p
   
  • Change Today:
      2.50p
  • 52 Week High: 1,671.00p
  • 52 Week Low: 1,264.00p
  • Currency: UK Pounds
  • Shares Issued: 4,096.39m
  • Volume: 4,204,672
  • Market Cap: £62,040m
  • RiskGrade: 129

GSK buys Boston's developmental liver disease drug for up to $2bn

By Benjamin Chiou

Date: Wednesday 14 May 2025

LONDON (ShareCast) - (Sharecast News) - GSK announced on Wednesday that it has entered into an agreement with Boston Pharmaceuticals to acquire its lead asset Efimosfermin for up to $2bn, buying a specialty medicine to treat and prevent progression of steatotic liver disease (SLD).
Under the terms of the deal, GSK pay Boston $1.2bn upfront, with the potential for additional success-based milestone payments totalling $800m.

The acquisition will expand the British pharma giant's hepatology pipeline aimed at addressing steatotic and viral drivers of liver disease, offering multiple development options with the potential for first launch in 2029.

Efimosfermin is a once-monthly fibroblast growth factor 21 (FGF21) analog therapeutic ready for phase III development. Phase II data showed the potential for the drug to reverse liver fibrosis, demonstrated in metabolic dysfunction-associated steatohepatitis, otherwise known as MASH.

SLD, which affects up to 5% of the global population, represents an area of "significant unmet medical need" with limited treatment options, GSK said.

"Interventions that reduce moderate-to-advanced fibrosis to prevent progression of cirrhosis, liver cancer, hospitalisations and transplant could save the US healthcare system between $40-100bn over the next two decades," the company said.

"The FGF21 class has shown some of the most exciting data in MASH including first-in-disease evidence of cirrhosis reversal, and Efimosfermin has the potential to define a new standard-of-care with its monthly dosing and tolerability profile," said Tony Wood, GSK's chief scientific officer.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

GSK Market Data

Currency UK Pounds
Share Price 1,514.50p
Change Today 2.50p
% Change 0.17 %
52 Week High 1,671.00p
52 Week Low 1,264.00p
Volume 4,204,672
Shares Issued 4,096.39m
Market Cap £62,040m
RiskGrade 129

GSK Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
56.09% below the market average56.09% below the market average56.09% below the market average56.09% below the market average56.09% below the market average
39.13% above the sector average39.13% above the sector average39.13% above the sector average39.13% above the sector average39.13% above the sector average
Price Trend
36.06% above the market average36.06% above the market average36.06% above the market average36.06% above the market average36.06% above the market average
55.56% above the sector average55.56% above the sector average55.56% above the sector average55.56% above the sector average55.56% above the sector average
Income
69.95% above the market average69.95% above the market average69.95% above the market average69.95% above the market average69.95% above the market average
100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average
Growth
35.95% below the market average35.95% below the market average35.95% below the market average35.95% below the market average35.95% below the market average
44.83% below the sector average44.83% below the sector average44.83% below the sector average44.83% below the sector average44.83% below the sector average

What The Brokers Say

Strong Buy 4
Buy 2
Neutral 14
Sell 3
Strong Sell 1
Total 24
neutral
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

GSK Dividends

  Latest Previous
  Q1 Q4
Ex-Div 15-May-25 20-Feb-25
Paid 10-Jul-25 10-Apr-25
Amount 16.00p 16.00p

Trades for 06-Jun-2025

Time Volume / Share Price
15:14 612 @ 1,514.50p
15:14 66 @ 1,514.62p
15:14 669 @ 1,514.50p
15:14 587 @ 1,514.50p
15:14 78 @ 1,514.69p

GSK Key Personnel

CEO Emma Walmsley

Top of Page